Cerebrovascular Thrombosis in Children Undergoing Treatment for ALL

Overview

This case series highlights the incidence and characteristics of cerebrovascular thrombosis in pediatric patients with acute lymphoblastic leukemia (ALL) undergoing PEG-asparaginase treatment. Notably, thrombotic events clustered within 5–17 days post-administration, with significant coagulation abnormalities observed at symptom onset.

Background

Cerebrovascular thrombosis is a rare but serious complication of chemotherapy in children with ALL, impacting morbidity and long-term outcomes. Understanding the timing and laboratory correlates of these events is crucial for improving patient management and outcomes. This study provides insights into the incidence and management of cerebrovascular events associated with PEG-asparaginase therapy.

Data Highlights

Key Findings

• Six out of 1,138 pediatric ALL patients developed cerebrovascular thrombosis (0.53% incidence).
• Five patients had cerebral venous sinus thrombosis (CVST) and one had acute ischemic stroke (AIS).
• All patients exhibited elevated D-dimer levels and reduced antithrombin III activity at symptom onset.
• Therapeutic low-molecular-weight heparin was administered to four patients with CVST, resulting in favorable outcomes.
• One AIS patient underwent successful mechanical thrombectomy with significant neurological improvement.
• No recurrent thrombotic events were observed during follow-up.

Clinical Implications

Clinicians should maintain a high index of suspicion for cerebrovascular thrombosis in pediatric ALL patients, particularly within 5–17 days following PEG-asparaginase administration. Close monitoring of coagulation parameters, including D-dimer and antithrombin III levels, may facilitate early diagnosis and intervention.

Conclusion

This study underscores the importance of recognizing the temporal pattern of cerebrovascular thrombosis in pediatric ALL therapy, advocating for vigilant monitoring and timely management to improve patient outcomes.

Related Resources & Content

1. Blood Cancer Journal, 2014 -- The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial
2. The ASCO Post, 2017 -- Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia
3. Blood Cancer Journal, 2024 -- Venous Thromboembolism Risk in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Undergoing Pediatric-Inspired Treatment Regimens
4. The ASCO Post, 2013 -- Postinduction Dexamethasone and Individualized Dosing of Asparaginase Improve Outcome in Pediatric ALL
5. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia - PMC
6. Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association
7. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents - PMC
8. Cerebral venous sinus thrombosis in pediatric ALL therapy
9. Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association
10. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents - PMC